Qin Huang Dao Shi

Researchers are evaluating the drug orforglipron in people who have obesity or are overweight and also suffer from osteoarthritis OA of the knee with pain. This study aims to assess how well and safely orforglipron works for this group of participants. The trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study sponsored by Eli Lilly and Company. Participation in the study will last about 74 weeks. Participants will be randomly assigned to receive orforglipron or a placebo orally. The study includes two independent groups under a master protocol, each comparing orforglipron to placebo. Treatment is given once daily, and the study design is parallel-arm, meaning participants remain in their assigned group throughout the trial. During the study, participants will undergo various assessments including pain evaluation using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function tests, body weight measurement, health surveys, walking tests, and blood tests for inflammation markers and cholesterol. Safety and drug levels will also be monitored. These evaluations occur from the beginning of the study through week 72, with participant involvement spanning about 74 weeks total.

Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.